Literature DB >> 23021371

Revertant mosaicism in heritable skin diseases: mechanisms of natural gene therapy.

Anna M G Pasmooij1, Marcel F Jonkman, Jouni Uitto.   

Abstract

Revertant mosaicism (RM) refers to the co-existence of cells carrying disease-causing mutations with cells in which the inherited mutation is genetically corrected by a spontaneous event. It has been discovered in an increasing number of heritable skin diseases: ichthyosis with confetti and different subtypes of epidermolysis bullosa. This "natural gene therapy" phenomenon manifests as normal appearing skin areas surrounded by affected skin. Although initially thought to be rare, RM is now considered relatively common in genetic skin diseases. To address the issues relevant to RM, we here discuss the following questions: 1) What is the incidence of RM in heritable skin diseases? 2) What are the repair mechanisms in RM? 3) When do the revertant mutations occur? 4) How do you recognize revertant skin? 5) Do the areas of RM change in size? The answers to these questions allow us to acquire knowledge on these reverted cells, the mechanisms of RM, and utility of the reverted cells to the advantage of the patient. The revertant skin could potentially be used to treat the patient's own affected skin.

Entities:  

Mesh:

Year:  2012        PMID: 23021371

Source DB:  PubMed          Journal:  Discov Med        ISSN: 1539-6509            Impact factor:   2.970


  31 in total

Review 1.  Induced pluripotent stem cells in dermatology: potentials, advances, and limitations.

Authors:  Ganna Bilousova; Dennis R Roop
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-03       Impact factor: 6.915

2.  Preliminary evaluation of cord blood platelet gel for the treatment of skin lesions in children with dystrophic epidermolysis bullosa.

Authors:  Gianluca Tadini; Sophie Guez; Lidia Pezzani; Maurizio Marconi; Noemi Greppi; Francesca Manzoni; Paolo Rebulla; Susanna Esposito
Journal:  Blood Transfus       Date:  2014-10-29       Impact factor: 3.443

Review 3.  From marrow to matrix: novel gene and cell therapies for epidermolysis bullosa.

Authors:  Beau R Webber; Jakub Tolar
Journal:  Mol Ther       Date:  2015-03-24       Impact factor: 11.454

Review 4.  The other side of the coin: the tumor-suppressive aspect of oncogenes and the oncogenic aspect of tumor-suppressive genes, such as those along the CCND-CDK4/6-RB axis.

Authors:  Xiaomin Lou; Ju Zhang; Siqi Liu; Ningzhi Xu; D Joshua Liao
Journal:  Cell Cycle       Date:  2014-05-05       Impact factor: 4.534

5.  Expanding the Mutation Spectrum of Ichthyosis with Confetti.

Authors:  Young H Lim; Keith A Choate
Journal:  J Invest Dermatol       Date:  2016-10       Impact factor: 8.551

Review 6.  Allogeneic blood and bone marrow cells for the treatment of severe epidermolysis bullosa: repair of the extracellular matrix.

Authors:  Jakub Tolar; John E Wagner
Journal:  Lancet       Date:  2013-10-05       Impact factor: 79.321

Review 7.  Modulating the stem cell niche for tissue regeneration.

Authors:  Steven W Lane; David A Williams; Fiona M Watt
Journal:  Nat Biotechnol       Date:  2014-08       Impact factor: 54.908

Review 8.  Cell therapy in dermatology.

Authors:  Gabriela Petrof; Alya Abdul-Wahab; John A McGrath
Journal:  Cold Spring Harb Perspect Med       Date:  2014-06-02       Impact factor: 6.915

Review 9.  [How frequently does genetic mosaicism occur in the skin?].

Authors:  R Happle
Journal:  Hautarzt       Date:  2014-06       Impact factor: 0.751

10.  [The many facets of inherited skin fragility].

Authors:  C Has; D Kiritsi
Journal:  Hautarzt       Date:  2014-06       Impact factor: 0.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.